Ribosome inactivating proteins (RIPs) from momordica charantia for anti viral therapy

Puri, M., Kaur, I., Kanwar, R. K., Gupta, R. C., Chauhan, A. and Kanwar, J. R. 2009, Ribosome inactivating proteins (RIPs) from momordica charantia for anti viral therapy, Current molecular medicine, vol. 9, no. 9, pp. 1080-1094.

Attached Files
Name Description MIMEType Size Downloads

Title Ribosome inactivating proteins (RIPs) from momordica charantia for anti viral therapy
Author(s) Puri, M.
Kaur, I.
Kanwar, R. K.
Gupta, R. C.
Chauhan, A.
Kanwar, J. R.
Journal name Current molecular medicine
Volume number 9
Issue number 9
Start page 1080
End page 1094
Total pages 15
Publisher Bentham Science Publishers
Place of publication Bussum, Netherlands
Publication date 2009
ISSN 1566-5240
1875-5666
Keyword(s) ribosome inactivating proteins
ant-viral
Summary This review describes the nature and applications of ribosome inactivating proteins (RIPs) from Momordica charantia (bitter melon). RIPs from the plant kingdom have received much attention in biomedical research because they target conserved host protein synthesis machinery and show specificity towards human and animal cell targets. Recent studies aimed at unravelling the enzymatic activities of the M charantia RIPs provide a structural basis for their activities. It has been reported that RIPs are member of the single chain ribosome inactivating protein (SCRIP) family which act irreversibly on ribosome by removing adenine residue from eukaryotic ribosomal RNA. Various activities of RIPs include anti-tumor, broad anti-viral, ribonuclease and deoxyribonuclease. MAP30 (Momordica Anti-HIV Protein), alpha- and beta-momorcharins inhibit HIV replication in acutely and chronically infected cells and thus are considered potential therapeutic agent in HIV infection and AIDS. Further, MAP30 improved the efficacy of anti-HIV therapy when used in combination with other anti-viral drugs. MAP30 holds therapeutic promise over other RIPs because not only it is active against infection and replication of both HSV and HIV but is non toxic to normal cells. Here we review the nature, action, structure function relationship and applications of RIPs from Momordica charantia and evaluate their potential for anti-cancer and anti-viral therapy.
Language eng
Field of Research 030406 Proteins and Peptides
100302 Bioprocessing, Bioproduction and Bioproducts
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
HERDC collection year 2009
Persistent URL http://hdl.handle.net/10536/DRO/DU:30019713

Document type: Journal Article
Collection: Centre for Biotechnology and Interdisciplinary Sciences (BioDeakin)
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 22 times in TR Web of Science
Scopus Citation Count Cited 23 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 473 Abstract Views, 6 File Downloads  -  Detailed Statistics
Created: Fri, 18 Sep 2009, 18:06:32 EST by Munish Puri

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.